BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2026)

BioNexus Gene Lab has disclosed Operating Expenses across 9 years of filings, most recently posting $597386.0 for Q1 2026.

• Operating Expenses for Q1 2026 came in at $597386.0, down 43.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 24.64% YoY), and the FY2025 annual result was $4.5 million, down 9.18% from the prior year.
• Operating Expenses came in at $597386.0 for Q1 2026 at BioNexus Gene Lab, down from $1.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.2 million in Q3 2023 to a low of -$4.0 million in Q4 2023.
• The 5-year median for Operating Expenses is $1.1 million (2025), against an average of $1.0 million.
• Across the five-year window, Operating Expenses jumped 1557.79% in 2022 and plunged 506.52% in 2023, its largest moves.
• BioNexus Gene Lab's Operating Expenses stood at $975716.0 in 2022, then slumped by 506.52% to -$4.0 million in 2023, then surged by 135.31% to $1.4 million in 2024, then retreated by 24.86% to $1.1 million in 2025, then slumped by 43.23% to $597386.0 in 2026.
• The last three Operating Expenses figures came in at $597386.0 (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.